Clinical Application of Optical Genome Mapping for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy that mainly affects skeletal muscle. FSHD1 accounts for 95% of all FSHD cases and can be diagnosed based on the pathogenic contraction of the D4Z4-repeat array on chromosome 4q35. Genetic diagnosis of FSHD1 is challenging because of the large size and repetitive nature of the D4Z4 region. We evaluated the clinical applicability of optical genome mapping (OGM) for the genetic diagnosis of FSHD1. Methods: We included 25 individuals with clinically confirmed or suspected/probable FSHD and their families. Ultra-high-molecular-weight DNA from peripheral blood was labeled, stained, and imaged using a single-molecule OGM platform (Bionano Genomics Saphyr system). D4Z4 repeat size and haplotype information were analyzed using the manufacturer’s dedicated pipeline. We also compared the workflow and test time between Southern blot analysis and OGM. Results: We obtained concordant OGM and Southern blot results with 10 samples from patients with clinically confirmed FSHD. The D4Z4 repeat size differed within 1 unit between the Southern blot analysis and OGM. Among nine patients with clinically suspected or probable FSHD, six patients were confirmed to have pathogenic contractions by OGM. In our cohort, one de novo mosaic FSHD1 patient was successfully diagnosed with OGM. Moreover, OGM has a more straightforward and less time-consuming workflow than Southern blot analysis. Conclusions: OGM enables accurate and reliable detection of pathogenic contraction of the D4Z4-repeat array and is a valuable tool for the genetic diagnosis of FSHD1.
Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy that mainly affects skeletal muscle. FSHD1 accounts for 95% of all FSHD cases and can be diagnosed based on the pathogenic contraction of the D4Z4-repeat array on chromosome 4q35. Genetic diagnosis of FSHD1 is challenging because of the large size and repetitive nature of the D4Z4 region. We evaluated the clinical applicability of optical genome mapping (OGM) for the genetic diagnosis of FSHD1. Methods: We included 25 individuals with clinically confirmed or suspected/probable FSHD and their families. Ultra-high-molecular-weight DNA from peripheral blood was labeled, stained, and imaged using a single-molecule OGM platform (Bionano Genomics Saphyr system). D4Z4 repeat size and haplotype information were analyzed using the manufacturer’s dedicated pipeline. We also compared the workflow and test time between Southern blot analysis and OGM. Results: We obtained concordant OGM and Southern blot results with 10 samples from patients with clinically confirmed FSHD. The D4Z4 repeat size differed within 1 unit between the Southern blot analysis and OGM. Among nine patients with clinically suspected or probable FSHD, six patients were confirmed to have pathogenic contractions by OGM. In our cohort, one de novo mosaic FSHD1 patient was successfully diagnosed with OGM. Moreover, OGM has a more straightforward and less time-consuming workflow than Southern blot analysis. Conclusions: OGM enables accurate and reliable detection of pathogenic contraction of the D4Z4-repeat array and is a valuable tool for the genetic diagnosis of FSHD1.
참고문헌 (27)
- Padberg GW, "Facioscapulohumeral muscular dystrophy in the Dutch population", Muscle Nerve Suppl, 2, pp.S81~S84 (1995)
- van der Maarel SM, "De novo facioscapulohumeral muscular dystrophy:frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10", Am J Hum Genet, 66, pp.26~35 (2000)
- Tawil R, "Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine", Neurology, 85, pp.357~364 (2015)
- Gabriëls J, "Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element", Gene, 236, pp.25~32 (1999)
- Hamel J, "Facioscapulohumeral muscular dystrophy : update on pathogenesis and future treatments", Neurotherapeutics, 15, pp.863~871 (2018)
- Bakker E, "The FSHD-linked locus D4F104S1(p13E-11)on 4q35 has a homologue on 10qter", Muscle Nerve Suppl, 2, pp.S39~S44 (1995)
- Deidda G, "Physical mapping evidence for a duplicated region on chromosome 10qter showing high homology with the facioscapulohumeral muscular dystrophy locus on chromosome 4qter", Eur J Hum Genet, 3, pp.155~167 (1995)
- Lemmers RJLF, "Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere", Nat Genet, 32, pp.235~236 (2002)
- Wang LH, "Facioscapulohumeral dystrophy", Curr Neurol Neurosci Rep, 16, pp.66~ (2016)
- Lemmers RJLF, "Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2", Hum Mol Genet, 24, pp.659~669 (2015)
- van den Boogaard ML, "Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy", Am J Hum Genet, 98, pp.1020~1029 (2016)
- Mul K, "Phenotype-genotype relations in facioscapulohumeral muscular dystrophy type 1", Clin Genet, 94, pp.521~527 (2018)
- Statland JM, "Risk of functional impairment in facioscapulohumeral muscular dystrophy", Muscle Nerve, 49, pp.520~527 (2014)
- Lunt PW, "Phenotypic-genotypic correlation will assist genetic counseling in 4q35-facioscapulohumeral muscular dystrophy", Muscle Nerve Suppl, 2, pp.S103~S109 (1995)
- Banerji CRS, "Facioscapulohumeral muscular dystrophy 1 patients participating in the UK FSHD registry can be subdivided into 4 patterns of selfreported symptoms", Neuromuscul Disord, 30, pp.315~328 (2020)
- Lin F, "New insights into genotypephenotype correlations in Chinese facioscapulohumeral muscular dystrophy : a retrospective analysis of 178 patients", Chin Med J(Engl), 128, pp.1707~1713 (2015)
- Lemmers RJLF, "Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy : workshop 9th June 2010, LUMC, Leiden, The Netherlands", Neuromuscul Disord, 22, pp.463~470 (2012)
- Lemmers RJLF, "D4F104S1 deletion in facioscapulohumeral muscular dystrophy:phenotype, size, and detection", Neurology, 61, pp.178~183 (2003)
- Lemmers RJLF, "Somatic mosaicism in FSHD often goes undetected", Ann Neurol, 55, pp.845~850 (2004)
- Stence AA, "Validation of optical genome mapping for the molecular diagnosis of facioscapulohumeral muscular dystrophy", J Mol Diagn, 23, pp.1506~1514 (2021)
- Zhang Q, "Clinical application of single-molecule optical mapping to a multigeneration FSHD1 pedigree", Mol Genet Genomic Med, 7, pp.e565~ (2019)
- Dai Y, "Single-molecule optical mapping enables quantitative measurement of D4Z4 repeats in facioscapulohumeral muscular dystrophy(FSHD)", J Med Genet, 57, pp.109~120 (2020)
- Mitsuhashi S, "Nanopore-based single molecule sequencing of the D4Z4array responsible for facioscapulohumeral muscular dystrophy", Sci Rep, 7, pp.14789~ (2017)
- Delourme M, "Complex 4q35 and 10q26 rearrangements : a challenge for molecular diagnosis of patients with facioscapulohumeral dystrophy", Neurol Genet, 9, pp.e200076~ (2023)
- Ricci E, "Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype", Ann Neurol, 45, pp.751~757 (1999)
- van Overveld PGM, "Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy", Ann Neurol, 58, pp.569~576 (2005)
- Park HJ, "Low D4Z4copy number and gender difference in Korean patients with facioscapulohumeral muscular dystrophy type 1", Neuromuscul Disord, 25, pp.859~864 (2015)